EP0572494A1 — Composition for use in transdermal administration
Assigned to Commonwealth Scientific and Industrial Research Organization CSIRO · Expires 1993-12-08 · 32y expired
What this patent protects
The invention relates to a composition for transdermally administering an agent with biological activity, comprising said agent with biological activity and a vector tolerable in pharmacology, and in which said agent with biological activity is present in the vector in a concentr…
USPTO Abstract
The invention relates to a composition for transdermally administering an agent with biological activity, comprising said agent with biological activity and a vector tolerable in pharmacology, and in which said agent with biological activity is present in the vector in a concentration greater than that of its solubility limit under ambient conditions, the quantity of finely dispersed solid particles of said agent in the vector being sufficient to significantly facilitate the dermal transfer of said composition. The invention also relates to a process for the preparation of such compositions.
Drugs covered by this patent
- Risperdal (risperidone) · Johnson & Johnson (Janssen)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.